Clinical Trial Update: TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients [Phase 1]

View source ↗

Summary

Phase 1 study of TQ05105 tablet for myelofibrosis in patients resistant or intolerant to ruxolitinib has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• TQ05105 Tablet

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Myelofibrosis | Phase 1 | Status: TERMINATED